COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Comparison of Candida Eradication and Serum Cidal Activity of Echinocandins

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00839540
Recruitment Status : Completed
First Posted : February 9, 2009
Results First Posted : February 24, 2012
Last Update Posted : February 28, 2012
Astellas Pharma US, Inc.
Information provided by (Responsible Party):
Gary E. Stein, Pharm.D., Michigan State University

Brief Summary:

The purpose of this pharmacokinetic (PK) and pharmacodynamic (PD) study is:

To study the rate and duration of serum cidal activity of caspofungin (CFG) and micafungin (MFG) against Candida isolates from the subject and against Candida glabrata with varying degrees of caspofungin susceptibilities.

This investigation will provide clinicians information supporting the use of caspofungin and micafungin in situations where Candida strains may be a cause of infection.

Condition or disease Intervention/treatment Phase
Candidemia Drug: micafungin Drug: Micafungin Drug: Caspofungin Phase 4

Detailed Description:


Patients - Adult patients with presumptive candidemia. Patients with severe neutropenia (<500) APACHE II scores > 20, or significant liver disease will be excluded. All will give written informed consent (Pappas et al. CID. Oct 1, 2007).

Drugs - Patients will receive either CFG: 70 mg loading dose (LD) followed by 50 mg once daily (qd) (8 patients), MFG: 100 mg qd (8 patients) or MFG: 200 mg qd (8 patients). All agents will be given by slow IV infusion (MFG will be supplied by Astellas).

Sera - Blood samples will be collected at the end of the infusion (peak) and at 12 h and 24 h (trough) after the beginning of an infusion (day 3-4).

Each patients sera will be tested (MIC and cidal activity) against their own Candida isolate (if isolated). In addition, recent clinical isolates of C. glabrata will also be tested against patient sera (time-kill) to verify previous in vitro and animal PD studies (Cota. AAC. Nov. 2006; Wiederhold. AAC. May 2007).


  • Patient outcome, including Candida eradication, will be documented for each patient by repeat culture.
  • Serum concentrations (lab to be determined) and PK analysis of each echinocandin will be determined for each patient.
  • Serum cidal titers will be measured against each of the Candida isolates for each agent at each time period. Median and geometric mean Peak and duration of cidal activity will then be determined and compared.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 21 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Comparison of Candida Eradication and Serum Cidal Activity of Echinocandins in Patients With Presumptive Candidemia
Study Start Date : December 2008
Actual Primary Completion Date : May 2010
Actual Study Completion Date : May 2010

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: micafungin 100
Patients receive Micafungin 100 mg qd
Drug: micafungin
100 mg qd by slow IV infusion for 24 h
Other Name: Micamine

Active Comparator: micafungin 200
Patients receive 200 mg Micafungin qd
Drug: Micafungin
200 mg qd by slow IV infusion for 24 h
Other Name: Micamine

Active Comparator: Caspofungin
Patients receive caspofungin 70 mg LD followed by 50 mg qd
Drug: Caspofungin
70 mg LD followed by 50 mg qd by slow IV infusion for 24 h
Other Name: Cancidas

Primary Outcome Measures :
  1. Serum Cidal Activity as Tested Against Various Candida Isolates and Reported as Ex-vivo Effect (Log Inhibition of Growth) [ Time Frame: Pre-treatment, 1.5 hour (h), 12 h and 24 h after receiving the drug ]

    Serum cidal activity of serum collected at different timepoints from the patients will be tested against various Candida isolates and the ex-vivo effect reported as log inhibition (logrithmic measurement of the decrease in microbiological growth).

    These Candida isolates had a range of minimum inhibitory concentrations (MIC) to Caspofungin (C) and Micafungin (M).

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Adult patients with presumptive candidemia

Exclusion Criteria:

  • Patients with severe neutropenia (<500)
  • Patients with APACHE II scores > 20
  • Patients with severe liver disease

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00839540

Layout table for location information
United States, Michigan
Sparrow Hospital
Lansing, Michigan, United States, 48912
Sponsors and Collaborators
Gary E. Stein, Pharm.D.
Astellas Pharma US, Inc.
Layout table for investigator information
Principal Investigator: Gary E Stein, Pharm.D. Michigan State University
Layout table for additonal information
Responsible Party: Gary E. Stein, Pharm.D., Professor of Medicine, Michigan State University Identifier: NCT00839540    
Other Study ID Numbers: PA-07-004
First Posted: February 9, 2009    Key Record Dates
Results First Posted: February 24, 2012
Last Update Posted: February 28, 2012
Last Verified: February 2012
Keywords provided by Gary E. Stein, Pharm.D., Michigan State University:
Additional relevant MeSH terms:
Layout table for MeSH terms
Candidiasis, Invasive
Invasive Fungal Infections
Systemic Inflammatory Response Syndrome
Pathologic Processes
Antifungal Agents
Anti-Infective Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action